Michael Siluk/Getty ImagesGLP-1 medications for weight loss are biting into large employers’ budgets, and in some cases coverage has become financially untenable, recent examples sugg
est.Bank of America CEO Brian Moynihan recently said that the company is spending more than $250 million annually on GLP-1s, representing 13% of its total healthcare spending. BofA has no plans to drop coverage, though, as Moynihan cited both short- and long-term benefits for the workforce and the bank, which anticipates
https://www.hr-brew.com/stories/large-employers-glp-1-medications?utm_source=&utm_medium=syndication&utm_campaign=feed